Safety, pharmacokinetics, and efficacy of subcutaneous isatuximab in adults with warm autoimmunehemolytic anemia

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 23

Inclusion Criteria

- Participant must be =18 to years of age, inclusive, at the time of signing the informed
consent.
- Males and females with a confirmed diagnosis of primary w AIHA or systemic lupus
erythematosus (SLE)-associated w AIHA (without other SLE-related manifestations apart
from cutaneous and musculoskeletal manifestations) who meet the following criteria:
a) Hemoglobin level <10 g/dL at screening.
b) Hemolysis (haptoglobin =40 mg/dL and total bilirubin above the
upper limit of normal).
c) Positive direct antiglobulin test (DAT) (IgG or IgG + complement C3d pattern or IgM
warm autoantibodies (positive dual DAT)).
- Participants who have previously failed to maintain a sustained response after treatment
with corticosteroids (corticosteroid-refractory or corticosteroid-dependent primary wAIHA).
- Part A only: Participants who have previously failed to maintain a sustained response
after treatment with rituximab (or other anti-CD20 monoclonal antibodies). The last dose
of the anti-CD20 antibody must have been administered at least 12 weeks before
enrollment.
- Part B: Participants who have had an insufficient response to at least 1 prior therapy in
addition to corticosteroids (splenectomy is regarded as a prior therapy).
- Contraceptive use by men and women
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 17
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 6

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:
- Clinically significant medical history or ongoing chronic illness that
would jeopardize the safety of the participant or compromise the quality of the data derived from his or her participation in the study as determined by the Investigator.
- Serious infection that required hospitalization within 3 months prior to enrollment.
- Secondary wAIHA from any cause including drugs, lymphoproliferative disorders, infectious or autoimmune disease (SLE without other SLE related manifestations apart from cutaneous and musculoskeletal manifestations is allowed), or active hematologic malignancies.
Participants with positive antinuclear antibodies but without a definitive diagnosis of an autoimmune disease are allowed.
- History of coagulation or bleeding disorders (Evans Syndrome is
allowed).
- Uncontrolled or active HBV or HCV infection
- HIV infection.
- Serum gammaglobulin levels <3 g/L.
- Females who are pregnant, lactating, or considered unreliable with
respect to contraceptive practice.
- Concurrent treatment with corticosteroids, unless the participant has been on a stable daily dose for = 30 days prior to enrollment.
- Treatment with cyclophosphamide within 4 weeks prior to enrollment.
- Treatment with cytotoxic drugs (other than cyclophosphamide) within 12 weeks prior to enrollment.

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials